Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nasal spray bevacizumab for epistaxis in hereditary hemorrhagic telangiectasia
2013-004204-19Phase 2Completed
- Sponsor
- Hospices Civils de Lyon
- Start
- Jun 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of bevacizumab in hereditary hemorrhagic telangiectasia (HHT) (4 arms), sponsored by Hospices Civils de Lyon. Primary endpoint: Average monthly duration of epistaxis. Started Jun 2015; status: completed.
02
Drugs
bevacizumab
03
Conditions
hereditary hemorrhagic telangiectasia (HHT)
Beyond the preview
Go deeper on 2013-004204-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004204-19.